Concord Biotech IPO

Concord Biotech is a prominent global developer and manufacturer of select fermentation-based APIs. They specialise in therapeutic areas such as immunosuppressants, oncology, and anti-infectives. With a substantial market share, the company supplies its products to over 70 countries, including regulated markets like the United States, Europe, Japan, and India. In 2022, the company commanded a market share of over 20% by volume for identified fermentation-based API products, such as mupirocin, sirolimus, tacrolimus, mycophenolate sodium, and cyclosporine. As of March 31, 2023, their total installed fermentation capacity was 1,250 m3. Over the years, the company has expanded its formulation business in India and various emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore, and Paraguay. ;